All News - ALZFORUM
WEB4 days ago · At the Edge of Spatial Omics, Cellular Response to Amyloid Comes into View. Add To My AlzForum. 27 Aug 2024. At AAIC, scientists linked Alzheimer’s pathology to the demise of nearby neurons, and implicated plaque-adjacent glia in sparking tau pathology.
ALZFORUM | NETWORKING FOR A CURE
WEBSep 20, 2024 · Read our full coverage online or download the PDF. Sporadic Alzheimer’s is a complex disease caused by a convergence of genetic, environmental, and health factors that may vary from person to person. To model this heterogeneity and pave the way for medicines targeting different manifestations, the MODEL-AD …
2023—A Bumper Year for the Treatment and Science of Alzheimer's
WEBDec 26, 2023 · Lecanemab (bottom panel) reduced plaque load over the same period. [Courtesy of Eisai.] Alzforum's raison d'etre, it could be said, is to facilitate the search for treatments for Alzheimer's and related diseases. The year 2023 was a good year for this, as the U.S. FDA approved several drugs, compared to none in 2022.
A New Era of Alzheimer’s Treatment - ALZFORUM
WEBFollow News Comments. 22 Jun 2021. The Food and Drug Administration’s decision to greenlight aducanumab (trade name Aduhelm) for Alzheimer’s disease has touched off an explosion of criticism and debate (see Part 1 of this series). Some researchers, however, consider the approval an overall positive development that the neurodegeneration ...
Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline ...
WEBOct 12, 2022 · Alzheimer’s researchers hailed the news as a major advance. In particular, they welcomed the straightforward findings after the highly contested rollout of aducanumab last year. “What the field needed was a clearly positive result from a trial completed and conducted per protocol,” Gil Rabinovici at the University of California, San ...
FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.
WEB10 May 2024. For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and blood tests for Alzheimer’s disease, were able to be marketed without providing proof of accuracy in the intended population. Now, the ...
Do Two APOE4 Alleles Always Mean Alzheimer's? - ALZFORUM
WEBTools. 10 May 2024. For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists make the case that people with two APOE4 alleles are not merely at risk, but are destined to develop AD. As reported in Nature Medicine on May 6, researchers led by ...
Aducanumab Approved to Treat Alzheimer’s Disease
WEB07 Jun 2021. In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid antibody aducanumab, now called Aduhelm, removes amyloid plaque from the brain, but its ability to slow cognitive decline has ...
Revised Again: Alzheimer's Diagnostic Criteria Get Another …
WEBSep 16, 2022 · 17 Aug 2023. Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system.
How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
WEBOct 7, 2022 · For the first time, patients could get a prescription for a disease-modifying treatment along with their Alzheimer’s diagnosis. With two more antibodies in pivotal trials slated to read out completed Phase 3s within the next six months, and aducanumab already approved, the age of amyloid immunotherapy has truly been inaugurated. Cost, safety ...